MARKET

MRKR

MRKR

Marker Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3685
+0.0142
+4.01%
Opening 10:14 08/18 EDT
OPEN
0.3500
PREV CLOSE
0.3543
HIGH
0.3740
LOW
0.3500
VOLUME
94.28K
TURNOVER
21.34K
52 WEEK HIGH
2.050
52 WEEK LOW
0.2500
MARKET CAP
30.81M
P/E (TTM)
-0.7416
1D
5D
1M
3M
1Y
5Y
BRIEF-Marker Therapeutics Reports Q2 2022 Operating And Financial Results
BRIEF-Marker Therapeutics Reports Q2 2022 Operating And Financial Results
Reuters · 6d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Investor Place · 08/08 11:29
Nasdaq Falls Over 100 Points, Marker Therapeutics Shares Spike Higher
U.S. stocks traded mostly lower toward the end of trading, following the release of jobs data
Benzinga · 08/05 19:06
Dow Drops 150 Points, Crude Oil Rises Over 2%
U.S. stocks traded lower midway through trading, following the release of jobs data
Benzinga · 08/05 16:02
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Investor Place · 08/05 11:29
BRIEF-Marker Therapeutics Announces FDA Clearance Of IND For MT-601 For Treatment Of Relapsed/Refractory Non-Hodgkin Lymphoma
BRIEF-Marker Therapeutics Announces FDA Clearance Of IND For MT-601 For Treatment Of Relapsed/Refractory Non-Hodgkin Lymphoma
Reuters · 08/04 21:51
Marker Therapeutics Shares Jump 60 Percent As FDA Announced Clearance To Blood Cell Cancer Study
The U.S. Food and Drug Administration (FDA) announced clearance to Marker Therapeutics’ (NASDAQ: MRKR) Investigational New Drug (IND) application for MT-601 for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma.
Benzinga · 08/04 21:01
Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma
Company expects to initiate Phase 1 trial of MT-601 in r/r NHL in 2023HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-ba...
GlobeNewswire · 08/04 20:37
More
No Data
Learn about the latest financial forecast of MRKR. Analyze the recent business situations of Marker Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MRKR stock price target is 2.167 with a high estimate of 4.000 and a low estimate of 1.000.
High4.000
Average2.167
Low1.000
Current 0.3600
EPS
Actual
Estimate
-0.12-0.09-0.06-0.03
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 88
Institutional Holdings: 27.60M
% Owned: 33.01%
Shares Outstanding: 83.60M
TypeInstitutionsShares
Increased
10
1.47M
New
5
65.26K
Decreased
11
2.52M
Sold Out
18
1.72M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.44%
Pharmaceuticals & Medical Research
-0.51%
Key Executives
Non-Executive Chairman/Independent Director
N. David Eansor
President/Chief Executive Officer/Director
Peter Hoang
Chief Financial Officer
Anthony Kim
Chief Operating Officer/Chief Scientific Officer/Director
Juan Vera
Chief Accounting Officer/Treasurer/Secretary
Michael Loiacono
Vice President - Operations
Gerald Garrett
Vice President
Nadia Agopyan
Vice President
Anna Szymanska
Vice President - Research & Development
Tsvetelina Hoang
Other
Mythili Koneru
Independent Director
Steven Elms
Independent Director
Katharine Knobil
Independent Director
David Laskow-Pooley
Independent Director
John Wilson
No Data
No Data
About MRKR
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The Company has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. It has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The Company is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.

Webull offers kinds of Marker Therapeutics Inc stock information, including NASDAQ:MRKR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRKR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRKR stock methods without spending real money on the virtual paper trading platform.